Big pharmaceutical companies traditionally poured a lot of money into internal scientific research, said Laura Schoppe of Fuentek, a consulting service that helps universities, government labs and companies bring technology to market. But in the wake of the economic downturn, they are “trying to leverage other people taking that early-stage risk – and then, once it’s a little bit more proven, they come in and buy it or augment it,” she said.